Syros Pharmaceuticals, Inc. (0LC7.L)

2.9020 +0.2920 (+11.19%) At close: 04:58PM GMT

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com

Sector(s): 
Industry: 
Full-time employees: 117

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Nancy A. Simonian M.D.	President, CEO & Director	955.39k	N/A	1961
Dr. Richard A. Young Ph.D.	Scientific Founder, Member of Scientific Advisory Board & Director	108.37k	N/A	1954
Dr. David A. Roth M.D.	Chief Medical Officer	679.52k	N/A	1963
Dr. James E. Bradner M.D.	Founder	N/A	N/A	1972
Dr. Nathanael S. Gray Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Jason Haas	Chief Financial Officer	457.22k	N/A	1968
Ms. Karen Hunady M.S.	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Gerald E. Quirk Esq., J.D.	Chief Legal & Compliance Officer	127.07k	N/A	1968
Ms. Lisa Roberts	Vice President of Human Resources	N/A	N/A	N/A
Ms. Kristin Stephens	Chief Development Officer	N/A	N/A	1973

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Syros Pharmaceuticals, Inc.’s ISS governance QualityScore as of 28 November 2023 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.